Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Heuser

Showing results (81-90 of 157) with videos related to

Pageof 16
Sort By:
Leukemia|June 9, 2006
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networksF J T Staal, G Cario, G Cazzaniga, et al.
Leukemia|June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groupsF Damm, F Thol, I Hollink, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|May 23, 2014
Low frequency of calreticulin mutations in MDS patientsM Heuser, V Panagiota, C Koenecke, et al.
Leukemia|May 8, 2013
SETBP1 mutation analysis in 944 patients with MDS and AMLF Thol, K J Suchanek, C Koenecke, et al.
Leukemia|April 12, 2016
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateA Chaturvedi, M M Araujo Cruz, N Jyotsana, et al.
Leukemia|November 9, 2011
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implicationsF Damm, F Thol, O Kosmider, et al.
Leukemia|August 30, 2012
Analysis of NUP98/NSD1 translocations in adult AML and MDS patientsF Thol, B Kölking, I H I Hollink, et al.
Scientific Reports|September 8, 2023
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemiaR F Schlenk, D Weber, J Krzykalla, et al.
Bone Marrow Transplantation|April 26, 2016
Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working PartyC Koenecke, D Heim, A van Biezen, et al.
Pageof 16

Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
Leukemia|June 9, 2006
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networksF J T Staal, G Cario, G Cazzaniga, et al.
Leukemia|June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groupsF Damm, F Thol, I Hollink, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|May 23, 2014
Low frequency of calreticulin mutations in MDS patientsM Heuser, V Panagiota, C Koenecke, et al.
Leukemia|May 8, 2013
SETBP1 mutation analysis in 944 patients with MDS and AMLF Thol, K J Suchanek, C Koenecke, et al.
Leukemia|April 12, 2016
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateA Chaturvedi, M M Araujo Cruz, N Jyotsana, et al.
Leukemia|November 9, 2011
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implicationsF Damm, F Thol, O Kosmider, et al.
Leukemia|August 30, 2012
Analysis of NUP98/NSD1 translocations in adult AML and MDS patientsF Thol, B Kölking, I H I Hollink, et al.
Scientific Reports|September 8, 2023
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemiaR F Schlenk, D Weber, J Krzykalla, et al.
Bone Marrow Transplantation|April 26, 2016
Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working PartyC Koenecke, D Heim, A van Biezen, et al.
Pageof 16